Aakash Desai: Our Commentary on Real-World Treatment Patterns After Platinum + IO in Advanced NSCLC
Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“Just published in JAMA, Journal of the American Medical Association Open Network — Our commentary on real-world treatment patterns after platinum + IO in advanced NSCLC, led by Dr. Vamsi Velcheti and colleagues:
This large retrospective cohort of 1,793 patients offers a sobering view of outcomes after first-line therapy in metastatic NSCLC:
- Median OS: 11.2 months
- Most common regimens: Docetaxel ± ramucirumab
- 131 different next-line strategies used
- IO rechallenge in ~16%
- Nearly 40% received ≥1 additional line
The data underscore the complexity of post-progression care—and the urgent need for better sequencing, biomarker-guided therapies, and broader access to clinical trials.
Honored to co-author this with Dr. Chinmay Jani and Dr. GILBERTO de lima LOPES Junior
Title: Clinical Strategies for Advanced Non–Small Cell Lung Cancer
Authors: Chinmay T. Jani, Aakash Desai, Gilberto De Lima Lopes Jr
You can read the Full Article on JAMA Network
Title: Treatments and Outcomes After Platinum-Based Chemotherapy and Anti–PD-(L)1 in NSCLC
Authors: Vamsidhar Velcheti, Julia Moore, Caitlyn T. Solem
You can read the Full Article on JAMA Network
More posts featuring Aakash Desai.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023